BioArctic

BioArctic Financing Cash Flow

The Net Financing Cash Flow of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 26.91 M SEK. In the previous year, Net Financing Cash Flow was 5.69 M SEK — a change of 373.18% (higher).

Financing Cash Flow

26.91 MSEK

YoY

373.18%

Last updated:

Net Financing Cash Flow of BioArctic is 2025 26.91 M SEK. Net Financing Cash Flow of BioArctic was 2024 5.69 M SEK. It decreases by 373.18% higher compared to the previous year.

The BioArctic Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
-138.51 M SEK
Jan 1, 2019
-138.51 M SEK
Jan 1, 2020
-6.60 M SEK
Jan 1, 2021
-7.39 M SEK
Jan 1, 2022
-2.81 M SEK
Jan 1, 2023
14.06 M SEK
Jan 1, 2024
5.69 M SEK
Jan 1, 2025
26.91 M SEK
The BioArctic Financing Cash Flow history
YEARFinancing Cash FlowYoY
26.91 MSEK+373.18%
5.69 MSEK-59.57%
14.06 MSEK-600.85%
-2.81 MSEK-62.00%
-7.39 MSEK+11.99%
-6.60 MSEK-95.24%
-138.51 MSEK0.00%
-138.51 MSEK-124.72%
560.22 MSEK-633.03%
-105.10 MSEK-2.10 M%
5,000.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Net Financing Cash Flow of BioArctic is 26.91 M SEK in 2025.

Net Financing Cash Flow of BioArctic changed from 5.69 M SEK to 26.91 M SEK, representing a 373.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow BioArctic since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioArctic

All Key Metrics — BioArctic